Takeda Joins the Dengue Vaccine Race with Inviragen Purchase
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 5 (Table of Contents)
Published: 20 May-2013
DOI: 10.3833/pdr.v2013.i5.1942 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In order to broaden its vaccine development pipeline, Takeda Pharmaceutical has agreed to acquire the Singaporean vaccine company Inviragen in a deal worth up to US$250 M, including US$35 M upfront...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS